Entire Transcript in Adobe Acrobat Format - National Reference ...

125
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
could commandeer laboratory space, and pipettes, and
beakers, and solutions, and so forth but we do not. We
regard those as things on which money has to be spent. I
want to understand if what we are talking about here is
simply a trade off. It would be more expensive.
Are you saying it would be logistically
impossible to have a code attached to each sample because
we are only talking here prospectively obviously, a code
attached to each sample and so if someone says I want to
have the available breast cancer -- the samples that meet
the following definitions that you would run the computer
and it would say, "Well, these women said you can study it
only for breast cancer and you are doing another study so
they are out and then these people said, 'I wanted to be
recontacted before you did a study,' so we will have to
contact them and if we are not willing to do that they are
out, and so forth."
Is it logistically impossible or is it simply a
matter that that would be an expense where someone would
have to pay the pathologist or the tissue bank or whatever
to do?
The third one is this thing that you came to
toward the end which was a reason for breaking the barrier
and you have cited one which would be an example of